The Wnt/ß-catenin-signaling pathway is modulated by androgen ablation therapy for advanced clinical prostate cancer and contributes to androgen independent cell growth
Androgen ablation therapy (AAT) is standard treatment for locally-advanced/metastatic prostate cancer (PCa).  Many patients develop castration-resistance (CRPCa) after ~2-3 years, with a poor prognosis.  The molecular mechanisms underlying CRPCa progression are unclear.  mRNA-Seq was performed on tumours from 7 patients with locally-advanced/metastatic PCa before and ~22 weeks after AAT initiation.  Differentially regulated genes were identified in treatment pairs. Overall design: Tumour biopsies from 7 patients were taken before and after AAT treatment